SLC22A5 and central nervous system cancer: Additionally, a therapeutic approach targeting both SLC22A5 and carnitine palmitoylotransferase 1 (CPT1), which mediates the formation of acylcarnitine from L-carnitine required for FAO, was demonstrated to reduce glioma cell proliferation and provoke persistent apoptosis [107].